Changeflow GovPing Pharma & Healthcare NCT07535723: Botulinum Toxin and GON Block for ...
Routine Notice Added Final

NCT07535723: Botulinum Toxin and GON Block for Chronic Migraine

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

A new randomized controlled trial (NCT07535723) was registered on ClinicalTrials.gov evaluating the combination of OnabotulinumtoxinA (Botox) injections with Greater Occipital Nerve (GON) block versus single therapy for chronic migraine patients. The trial will assess improvements in headache frequency, severity, and quality of life. Enrollment target and sponsor details were not specified in the registration record.

Published by NLM on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

A new clinical trial registration (NCT07535723) was added to ClinicalTrials.gov documenting a randomized controlled trial evaluating OnabotulinumtoxinA (Botox) injections combined with Greater Occipital Nerve (GON) block for chronic migraine treatment. The trial will compare combination therapy against single therapy approaches, measuring headache frequency, severity, and patient quality of life as primary outcomes.

Healthcare providers and clinical investigators conducting migraine research should be aware of this trial as it may influence treatment protocols and comparative effectiveness research. The study targets chronic migraine patients who may not have achieved adequate relief from standard preventive treatments. Results could inform future clinical practice guidelines for migraine management.

Archived snapshot

Apr 18, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Botulinum Toxin and/or Greater Occipital Nerve Block for Patients With Chronic Migraine

N/A NCT07535723 Kind: NA Apr 17, 2026

Abstract

Chronic migraine is a debilitating neurological disorder that significantly affects patients' daily functioning, mental health, and quality of life. Management typically includes acute and preventive treatments, but effectiveness can be limited due to medication overuse or delayed onset of action. OnabotulinumtoxinA injections provide proven long-term preventive benefits, while Greater Occipital Nerve (GON) block offers rapid but short-term relief. Although both treatments are used individually, evidence on the combined effect is limited. This randomized controlled trial aims to evaluate the efficacy and safety of combining OnabotulinumtoxinA injections with GON block, assessing improvements in headache frequency, severity, and patient quality of life compared to single therapy.

Conditions: Chronic Migraine Headache, OnabotulinumtoxinA, Greater Occipital Nerve Block, Combination Therapy

Interventions: OnabotulinumtoxinA, Greater Occipital Nerve Block (GONB)

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NLM.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NLM
Published
April 17th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07535723

Who this affects

Applies to
Clinical investigators Healthcare providers
Industry sector
6211 Healthcare Providers
Activity scope
Clinical trial registration Randomized controlled trial Combination therapy study
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Pharmaceuticals Medical Devices

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!